A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : BASDAI / Bath Ankylosing Spondylitis Disease Activity Index

[Related PubMed/MEDLINE]
Total Number of Papers: 762
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BASDAI  (>> Co-occurring Abbreviation)
Long Form:   Bath Ankylosing Spondylitis Disease Activity Index
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Adherence, Efficacy, and Safety of Wearable Technology-Assisted Combined Home-Based Exercise in Chinese Patients With Ankylosing Spondylitis: Randomized Pilot Controlled Clinical Trial. AS, ASDAS, BASFI, BASMI, PGA, PhGA
2022 Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe? AS, GFR, TNF
2022 Central Obesity in Axial Spondyloarthritis: The Missing Link to Understanding Worse Outcomes in Women? ASQoL, axSpA, BASFI, HAQ, WHR
2022 Comparison of ankylosing spondylitis patients with and without fibromyalgia syndrome according to the disease activation scores and response to treatment. AS, ASDAS, CRP, ESR, FM, HLA-B27
2022 Delayed treatment with a tumor necrosis factor alpha blocker associated with worse outcomes in patients with spondyloarthritis: data from the Czech National Registry ATTRA. ADA, ASDAS, axSpA, BASFI, EQ-5D, HAQ, OR, PROs, SF-36, TNF
2022 Disease Activity-Guided Stepwise Tapering but Not Discontinuation of Biologics Is a Feasible Therapeutic Strategy for Patients with Ankylosing Spondylitis: Real-World Evidence. AS, ASDAS-CRP, BASFI, ETN, LDA, PtGA
2022 Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. AS, HRQoL, PROs, SF-36v2, WPAI
2022 Effect of Warming Yang, Tonifying Kidney, and Removing Arthralgia Therapy on Cold-Dampness Arthralgia Type Ankylosing Spondylitis and Its Influence on the Levels of Humoral Factor in Human Serum. AS, BASFI, BMP-2, CXCL16, DKK1, IL-17, SOST, TCM, TNF-alpha, VAS
2022 Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. ASDAS, axSpA, LDA, nr-axSpA, r-axSpA, SEC, VLDA
10  2022 Efficacy of thunder-fire moxibustion in treating ankylosing spondylitis of kidney deficiency and governor meridian cold and its influence on TNF-α and RANKL: study protocol for a prospective, nonblinded, single-center, randomized controlled trial. AS, BASFI, RANKL, SF-36, TCM, TNF-alpha
11  2022 Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry. axSpA, bDMARD, WPAI
12  2022 Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France. ASDAS, axSpA, SEC
13  2022 Intravoxel incoherent motion diffusion-weighted imaging as a quantitative tool for evaluating disease activity in patients with axial spondyloarthritis. ADC, axSpA, BASFI, IVIM-DWI, MRI, PGA, SIJ, SPARCC
14  2022 Knockdown of circular RNA hsa_circ_0003307 inhibits synovial inflammation in ankylosing spondylitis by regulating the PI3K/AKT pathway. AS, BASFI, CRP, ELISA, ESR, FLS, HC, hsa, PBMCs, PI3K, qRT-PCR, TNF-alpha, TNFAIP2
15  2022 Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. ASDAS, CZP, nr-axSpA, OC, SFE, TEAE
16  2022 Measuring quality of life of patients with axial spondyloarthritis for economic evaluation. ASDAS, axSpA, BASFI
17  2022 Minimal Impact of the COVID-19 Pandemic on Disease Activity and Health-Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open-Label Extension Study. AS, ASDAS-CRP, ASQoL, HRQoL, OLE
18  2022 Monitoring of Disease Activity With a Smartphone App in Routine Clinical Care in Patients With Axial Spondyloarthritis. axSpA, PRO
19  2022 Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. ASDAS, axSpA, CRP, CV
20  2022 Prevalence and risk factors for uveitis in spondyloarthritis. OR, SpA
21  2022 Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis. AIDs, DMARDs, HC, SpA, YF
22  2022 Protective Effect and Possible Mechanisms of Tripterygium Glycosides in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis. ADR, AS, BASFI, CRP, ESR, RCTs, SP-VAS, TG
23  2022 Radiomic Quantification for MRI Assessment of Sacroiliac Joints of Patients with Spondyloarthritis. BASFI, CRP, ESR, MASES, MRI, SpA, SPAIR, STIR
24  2022 Real-World Effectiveness and Treatment Retention of Secukinumab in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: A Descriptive Observational Analysis of the Spanish BIOBADASER Registry. AS, ASDAS, bDMARDs, DAPSA, DAS28-CRP, IL-17A, PsA, SJC, TJC
25  2022 Relationship between inflammation and radiographic progression in patients with ankylosing spondylitis attaining a BASDAI of <4 during TNF inhibitor treatment. AS, CRP, mSASSS, TNFi
26  2022 Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO. ASDAS, axSpA, CRP, mSASSS, REGISPONSERBIO, TNFi
27  2022 The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis. AS, ASDAS, CRP, TCVGH
28  2022 The effect of exercise training programs with aerobic components on C-reactive protein, erythrocyte sedimentation rate and self-assessed disease activity in people with ankylosing spondylitis: A systematic review and meta-analysis. WMD
29  2022 The relationship between central sensitization and disease activity, quality of life, and sleep quality among patients with axial spondyloarthritis. ASDAS-CRP, axSpA, CS, CSI, HC, MASES, PSQI, QoL, SF-36, VAS
30  2022 The Relationship between Plasma Pentraxin 3 and Serum Amyloid P Levels and Disease Activity in Ankylosing Spondylitis. AS, ASDAS, CRP, ESR, PTX3, SAP
31  2022 The value of SPARCC sacroiliac MRI scoring in axial psoriatic arthritis and its association with other disease parameters. ASDAS, axPsA, CRP, DAPSA, MDA, MRI, SIJ, SIS, SPARCC
32  2022 Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. bDMARDs, HLA-B27, PsA, tsDMARDs
33  2022 Treatment with Tumour Necrosis Factor Inhibitors is Associated with a Time-Shifted Retardation of Radiographic Sacroiliitis Progression in Patients with Axial Spondyloarthritis: 10-year Results from the German Spondyloarthritis Inception Cohort. axSpA, CRP, NSAIDs, TNFi
34  2022 Upregulated lncRNA-NEF predicts recurrence and poor treatment outcomes of ankylosing spondylitis. AS, ASDAS, ESR, HFLS
35  2022 Validity and psychometric characteristics of the self-administered comorbidity questionnaire in patients with psoriatic arthritis. BMI, DAPSA, HAQ, PASI, PsA, PsAQoL, SCQ, SF-36
36  2022 Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry. ASDAS-CRP, axSpA, BASMI, MASES
37  2022 Which Metrological Index-the BASMI or EDASMI-is Best Correlated With Disease-Related Parameters in Spondylarthritis Patients? ASDAS, ASQoL, axSpA, BASFI, BASMI, BASRI, EDASMI, mSASSS
38  2022 Worse scores but similar patterns of disease activity: interpreting outcomes in women with axial spondyloarthropathy. ASQoL, ASRI, axSpA
39  2022 [Midterm follow-up outcomes of total hip arthroplasty in treatment for patients with juvenile-onset ankylosing spondylitis]. BASFI, HHS, JAS, MCS, PCS, THA
40  2022 [Therapeutic effects of complex multimodal rheumatologic treatment in the Rheumatology Center, Rhineland-Palatinate]. AS, BASFI, CMRT, DA, DAS28, PsA, RA, RA, RA, VAS
41  2021 Adalimumab and sulfasalazine in alleviating sacroiliac and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis: PETSPA. ADA, axSpA, PET/CT, SI, SSZ
42  2021 Alexithymia in ankylosing spondylitis. AS, ASQoL, BASFI, BASMI, BDI, TAS
43  2021 Angiotensin-Receptor Blockade Improves Inflammation and Endothelial Dysfunction in Ankylosing Spondylitis: ARB-AS Study. ARBs, AS, ASDAS, BASFI, CRP, CV, EPCs, ESR, FMD, HAQ-DI, ICAM-1, IL-1, QoL, SCORE, TBARS, TNF-alpha, VCAM-1
44  2021 Assessment of hip involvement in patients with ankylosing spondylitis: reliability and validity of the Hip Inflammation MRI Scoring System. AS, ASDAS, BASFI, BASRI-hip, CRP, HHS, HIMRISS, ICCs
45  2021 Assessment of plasma microRNA potentials as a non-invasive biomarker in patients with axial spondyloarthropathy. ASAS, miRNAs, qRT-PCR, rad-AxSpA
46  2021 Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project. AS, BMI, CARMA, CIRD, DAS28, PsA, RA
47  2021 Circular RNAs in peripheral blood mononuclear cells from ankylosing spondylitis. ALB, AS, ASA, AUC, circRNA, FC, GLOB, HC, hs-CRP, LY, mRNA, ncRNA, PBMCs, PLT, ROC, RT-qPCR
48  2021 Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs. bDMARD, csDMARD, DMARDs, PsA, PsAQoL, QoL
49  2021 Comparison of the effects of aerobic training alone versus aerobic training combined with clinical Pilates exercises on the functional and psychosocial status of patients with ankylosing spondylitis: A randomized controlled trial. 6MWT, AS, ASQoL, BASFI, BASMI, BST, CPE, HADS, MAF, PSQI, TSK
50  2021 Construct Validity of the Routine Assessment of Patient Index Data 3 (RAPID3) in the Evaluation of Axial Spondyloarthritis. ASDAS, axSpA, BASFI, mSASSS, RAPID3, ROC
51  2021 Correlation between C-Reactive Protein to Albumin Ratio and Disease Activity in Patients with Axial Spondyloarthritis. ALB, AUC, axSpA, BASFI, CRP, ESR, ROC
52  2021 Could C-Reactive Protein/Albumin Ratio be an Indicator of Activation in Axial Spondyloarthritis? axSpA, CRP, ESR, NLR
53  2021 Differences in stabilometric correlates of pain relief after wearing postural insoles for six weeks between chronic nociceptive and neuropathic foot pain. An open-label pilot study. BPI, NPSI, VAS
54  2021 Early Improvements in Disease Activity Indices Predict Long-Term Clinical Remission Suggested by the Treat-to-Target Strategy in Patients with Ankylosing Spondylitis Receiving TNF-alpha Inhibitor Treatment. AS, CI, CRP, GEEs, OR, TNFi
55  2021 Effectiveness and safety of Chinese herbal formula combined with western medicine for ankylosing spondylitis: A protocol for systematic review and meta-analysis. AS, BASFI, BASMI, CHF, CRP, ESR, GRADE, RCTs, ROBIS, SR, TCM
56  2021 Efficacy and safety of Fengshi Gutong Capsule in patients with active ankylosing spondylitis: A 4-week randomized controlled, double-blinded, double-dummy trial. AS, ASDAS-CRP, BASFI, BASMI, FSGTC, PGTA
57  2021 Efficacy and safety of thalidomide on psychological symptoms and sleep disturbances in the patient with refractory ankylosing spondylitis. AS, BASFI, BASMI
58  2021 Efficacy and Safety of Wenbu Zhibi Granule in Patients with Ankylosing Spondylitis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. AS, ASDAS, ASQoL, BASFI, BASMI, SPARCC, WZG
59  2021 Heart Involvement in a Moroccan Population with Spondyloarthritis: A Cross-sectional Study. AR, ASAS, ASDAS, AVT, BASFI, CVRF, ECG, MR, MS, RBBB, SpA, TTE
60  2021 HLA-B27 is associated with reduced disease activity in axial spondyloarthritis. axSpA, SpA
61  2021 Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. axSpA
62  2021 Impact of obesity on quality of life, psychological status, and disease activity in psoriatic arthritis: a multi‑center study. BMI, DAPSA, DAS28-CRP, FACIT, HADS, HAQ, HAQ-S, PASI, PsA, PsAQoL, VAS-F, VAS-P
63  2021 Influence of anti-TNF-α treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study. AS, AST, CRP, ESR, TNF-alpha
64  2021 Is There a Correlation Between Patient-Reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score and MRI Findings in Axial Spondyloarthropathy in Routine Clinical Practice? axSpA, MRI, PRO
65  2021 Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. ASAS, bDMARD, r-axSpA, TNFi
66  2021 Long noncoding RNA intersectin 1-2 gradually declines during adalimumab treatment, and its reduction correlates with treatment efficacy in patients with ankylosing spondylitis. AS, ASAS, ASDASCRP, CRP, IL, lnc-ITSN1-2, PBMC, TNF-alpha
67  2021 Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study. AS, ASDAS, CRP, TNF
68  2021 Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. PsA
69  2021 miRNA-451a and miRNA-125a Expression Levels in Ankylosing Spondylitis: Impact on Disease Diagnosis, Prognosis, and Outcomes. AS, AUC, miRNAs
70  2021 Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication. bDMARDs, SD
71  2021 Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. ASDAS-CRP, axSpA, CI, CV
72  2021 Predictors of Health-Related Quality of Life in Patients with Ankylosing Spondylitis in Southwest China. AS, BAS-G, BASFI, BDI-II, MCS, PCS, QoL
73  2021 Prevalence of Temporomandibular Joint Disorders in Patients with Ankylosing Spondylitis: A Cross-Sectional Study. AS, BASFI, HAQ-S, TMD
74  2021 Procollagen I N-terminal peptide correlates with inflammation on sacroiliac joint magnetic resonance imaging in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis: A cross-sectional study. AS, ASDAS, BASFI, CRP, ESR, MRI, nr-axSpA, OC, PINP, SIJ, SPARCC
75  2021 Relationship between periodontal status and disease activity in patients with ankylosing spondylitis. AS, ASQoL, BASFI, BASMI, GI, MASES, NSAID, PD, PI, TNF
76  2021 Reviewing Disease Activity Indices in Spondyloarthritis From the Sex Perspective: A Systematic Review and Metaanalysis. ASDAS, SpA
77  2021 Rheumatoid arthritis coexisting with ankylosing spondylitis: A report of 22 cases with delayed diagnosis. AS, DAS28, RA, RA/AS
78  2021 Serum IL-6 and TNF-α Levels Are Correlated with Disease Severity in Patients with Ankylosing Spondylitis. AS, CT, HCs, IL, TNF-alpha
79  2021 Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis. AS, BASFI, OPG, SMD, SMDs, sRANKL
80  2021 Structural Lesion Progression of the Sacroiliac Joint and Clinical Features in axSpA During TNFi Reduction: A Retrospective Cohort Study. ASDAS, axSpA, BASFI, DQ, SIJ, SPARCC, TNFi
81  2021 Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. ASDAS, ASQoL, BASFI, re
82  2021 SWE and SMI ultrasound techniques for monitoring needling treatment of ankylosing spondylitis: study protocol for a single-blinded randomized controlled trial. AS, ASQoL, BASFI, BASMI, CSA, FS-14, QoL, SIJ, SMI, SWE, VAS
83  2021 Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. AS, CRP, ESR, SII
84  2021 The association between elevated serum interleukin-22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study. ASDAS, axSpA, IL-22, mSASSS
85  2021 The Clinical and MRI Effect of TNF-α Inhibitors in Spondyloarthritis Patients With Hip Involvement: A Real-World Observational Clinical Study. ASDAS, BME, CRP, ESR, HIMRISS, SpA, TNF
86  2021 The Delay of Diagnosis in Spondyloarthropathy Patients in a Tertiary Hospital in Saudi Arabia. AS, ASDAS, CRP, DD, EnA, IBD, PsA, SpA
87  2021 The effect of Pulmonary Rehabilitation Programme on work productivity and clinical parameters in patients with ankylosing spondylitis. 6MWT, AS, ASQOL, BASFI, BDS, RFTs
88  2021 The evaluation of bone marrow edema in sacroiliac joint in patients with ankylosing spondylitis using magnetic resonance imaging Dixon sequence. AS, BASFI, CRP, ESR, MRI
89  2021 The Role of Clinical and Ultrasound Enthesitis Scores in Ankylosing Spondylitis. AS, ASDAS, BUSES, SpA, SPARCC
90  2021 The toll of unemployment in axial spondyloarthropathy: high prevalence and negative impact on outcomes captured in a national registry. ASRI, axSpA, HAQ
91  2021 The Value of Serum Amyloid A in the Diagnosis and Management of Ankylosing Spondylitis. AS, CRP, ESR, SAA
92  2021 Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study. axSpA, DAGDO, DAS28-CRP, LDA, TNFi
93  2021 Use of Quantitative Vertebral Bone Marrow Fat Fraction to Assess Disease Activity and Chronicity in Patients with Ankylosing Spondylitis. AS, ASDAS-CRP, BASFI, FF, MRI, mSASSS
94  2021 Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis:A randomized, crossover, agreement study. app, CIs, DANBIO, IA, MCID, PROMs
95  2021 Which factors explain the patient global assessment in patients with ankylosing spondylitis? A hierarchical cluster analysis on REGISPONSER-AS. AS, BAS-G, BASFI, MASES
96  2021 Yisaipu Provide AS Patients With an Economical Therapeutic Option While Original Biologicals are More Advantageous in the COVID-19 Epidemic Situation. AS, ASDAS-CRP, HAQ-S, PFS, TNF
97  2020 Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis. ASDAS, axSpA, BMI, SMDs
98  2020 Benefit of Biological Drugs for Quality of Life in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of Clinical Trials. AS, ASAS, ASQoL, BASFI, FACIT-F, QoL
99  2020 BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis. axSpA, CI, DAS28, RA, SAEs
100  2020 Biologic disease-modifying anti-rheumatic drugs and patient-reported outcomes in axial SpA: a systematic review and a call for action. ASQoL, axSpA, BASFI, bDMARDs, EQ-5D, FACIT-F, IL17Ai, MCID, nr-axSpA, PBO, PROs, r-axSpA, RCT, SF36-MCS, SF36-PCS, SLR, TNFi